Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 5/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24311969 | 0.83 | GAA (0.44) | CASP1GAANUDT1LMNASMN1; SMN2 | |
| SCHEMBL6180683 | 0.82 | CASP1 (0.45) | CASP1GAAPIK3C3PTPN11NUDT1 | |
| SCHEMBL5743790 | 0.81 | CASP1 (0.44) | CASP1GAAJAK2NUDT1LMNA | |
| SCHEMBL17619241 | 0.80 | LMNA (0.40) | GAAJAK2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29472130 | 0.80 | LMNA (0.40) | GAAJAK2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3943083 | 0.79 | ATR (0.54) | CASP1GAAALDH1A1HPGDATR | |
| SCHEMBL18754294 | 0.79 | ATR (0.43) | CASP1GAAPIK3C3NUDT1LMNA | |
| SCHEMBL3667384 | 0.78 | SMN1; SMN2 (0.55) | CASP1LMNASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL15645010 | 0.78 | KDM4E (0.42) | CASP1GAALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29439594 | 0.78 | SMN1; SMN2 (0.55) | CASP1LMNASMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20170057955-A1 | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | DPYD, PDXK, TYMP | CASP1 882/4885GAA 841/4885PIK3C3 1609/4885 |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | DPYD, TYMP, TOP2A | CASP1 1227/4885GAA 763/4885PIK3C3 1147/4885 |
| US-20170057955-A1 | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | KDM1B, KDM1A, KDM3B | CASP1 2484/4885GAA 1574/4885PIK3C3 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.